Pharmacogenetic testing in psychiatry, not (Quite) ready for primetime

Journal of Psychosocial Nursing and Mental Health Services

Volumn 52, Issue 11, 2014, Pages 13-16

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

GENETIC SCREENING; GENETICS; HUMAN; MENTAL DISORDERS; PHARMACOGENETICS; PROCEDURES; PSYCHIATRY;

GENETIC TESTING; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHIATRY; PSYCHOTROPIC DRUGS;

EID: 84928311170     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20141021-09     Document Type: Article

References (17)

1. Annas, G.J., & Bias, S. (2014). 23andMe and the FDA. New England Journal Medicine, 370, 985-988. doi:10.1056/NEJMP1316367
2. Drozda, K., Müller, D.J., & Bishop, J.R. (2014). Pharmacogenomic testing for neuropsychi-atric drugs: Current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy, 34, 166-184. doi:10.1002/phar.l398
3. Fagerness, J., Fonseca, E., Hess, G.P., Scott, R., Gardner, K.R., & Koffler, M. (2014). Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. American Journal of Managed Care, 20, el46-e1456.
4. Hall-Flavin, D.K., Winner, J.G., Allen, J.D., Carhart, J.M., Proctor, B., Snyder, K.A., Mrazek, D.A. (2013). Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetics Genomics, 23, 535-548. doi:10.1097/FPC.0b013e3283649b9a
5. Hall-Flavin, D.K., Winner, J.G, Allen, J.D., Jordan, J.J., Nesheim, R.S., Snyder, K.A., Mrazek, D.A. (2012). Using a pharmacogenomic algorithm to guide the treatment of depression. Translational Psychiatry, 2, e172. doi: 10.1038/tp.2012.99
6. National Human Genome Research Institute. (2014). Regulation of genetic tests [Web page]. Retrieved from http://www.genome.gov/10002335
7. Roche Molecular Diagnostics. (2014). AmpliChip CYP450 test [Web page]. Retrieved from http://molecular.roche.com/assays/Pages/AmpliChipCYP450Test.aspx
8. Rubinstein, W.S., Maglott, D.R., Lee, J.M., Katt-man, B.L., Malheiro, A.J., Ovetsky, M., Ostell, J.M. (2013). The NIH genetic testing registry: A new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Research, 41(Database issue), D925-D935.doi:10.1093/nar/gksll73
9. Salm, M., Abbate, K., Appelbaum, P., Ottman, R., Chung, W, Marder, K., Klitzman, R. (2014). Use of genetic tests among neurologists and psychiatrists: Knowledge, attitudes, behaviors, and needs for training. Journal of Genetic Counseling, 23, 156-163. doi: 10.1007/s10897-013-9624-0
10. Thakur, M., Grossman, I., McCory, D.C., Orlando, L.A., StefTens, D.C., Cline, K.E., Matchar, D.B. (2007). Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genetics in Medicine, 9, 826-835.
11. U.S. Food and Dmg Administration. (2014a). Clinical Laboratory Improvement Amendments (CLIA) [Web page]. Retrieved from bttp://www.fda.gov/medicaldevices/deviccregulationandguidance/ivdregulatoryassistance/ucm124105.htm
12. U.S. Food and Drug Administration. (2014b). Inspections, compliance, enforcement, and criminal investigations: 23andMe, Inc. 11/22/13 [Web page]. Retrieved from http://www.fda.gov/ICECI/EnforcementActions/WamingLetters/2013/ucm376296.htm
13. U.S. Food and Drug Administration. (2014c). Laboratory developed tests [Web page]. Retrieved from http://www.fda.gov/MedicalDevices/PrcxluctsiindMedicalProcedures/InVitroDiagnostics/ucm407296.htm
14. U.S. Food and Drug Administration. (2014d). Nucleic acid based tests [Web page]. Retrieved from bttp://www.fda.gov/MedicalDevices/ProductsiintlMedicalProcedtires/InVitroDiagnostics/ucm330711.htm
15. U.S. Food and Drug Administration. (2014e). Table of pharmacogenomic biomarkers in drug labeling [Web page]. Retrieved from http://www.fda.gov/drugs/scicnceresearch/researchareas/pharmacogenetics/ucm083378.htm
16. Winner, J., Allen, J.D., Altar, C.A., & Spahic-Mihajlovic, A. (2013). Psychiatric pharma-cogenomics predicts health resource utilization of outpatients with anxiety and depression. Translational Psychiatry, 3, e242. doi: 10.1038/tp.2013.2
17. Winner, J.G., Carhart, J.M., Altar, C.A., Allen, J.D., & Dechairo, B.M. (2013). A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discovery Medicine, 16, 219-227.